This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Trevena, Inc. [TRVN], a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, will visit the NASDAQ MarketSite in Times Square in celebration of its January 31 initial public offering (IPO) on The NASDAQ Stock Market.
In honor of the occasion,
Maxine Gowen, President and CEO, will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Wednesday, February 19, 2014 – 9:15 a.m. to 9:30 a.m. ET
Contact: Eliza Schleifstein (917) 763-8106
email@example.comNASDAQ MarketSite: Christine Barna (646) 441-5310
Christine.Barna@nasdaqomx.comFeed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page at:
For photos from ceremonies and events visit our Instagram Page:
For news tweets, please visit our Twitter page at:
For exciting viral content and ceremony photos visit our Tumblr Page:
A LiveStream of the NASDAQ Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Trevena, Inc. [TRVN]:
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated product candidates into the clinic – TRV027 to treat acute heart failure, TRV130 to treat moderate to severe acute pain intravenously, and TRV734 to treat moderate to severe acute and chronic pain orally. Trevena also plans to advance additional product candidates, including a preclinical program focused on central nervous system indications.